Based in Montréal and Toronto, CTI Life Sciences Fund, a Canadian venture firm makes venture capital investments in high quality emerging life science companies at the pre-clinical and clinical development stage in Canada and in the U.S. CTI Life Sciences Fund currently manage $245 million of assets.

Out of the four inflection points indicated in the figure below, the Fund’s strategy will be to focus on two key junctures in the pharmaceutical development process highlighted in color namely and primarily: from Pre-clinical to Proof-of-Concept and secondarily on Proof-of-Concept to Phase III.